Objective: Hypothermic machine perfusion may improve outcome after transplantation of kidneys donated after cardiac death (DCD), but no sufficiently powered prospective studies have been reported. Because organ shortage has led to an increased use of DCD kidneys, we aimed to compare hypothermic machine perfusion with the current standard of static cold storage preservation. Methods: Eighty-two kidney pairs from consecutive, controlled DCD donors 16 years or older were included in this randomized controlled trial in Eurotransplant. One kidney was randomly assigned to machine perfusion and the contralateral kidney to static cold storage according to computer-generated lists created by the permuted block method. Kidneys were allocated according to standard rules, with concealment of the preservation method. Primary endpoint was delayed graft function (DGF), defined as dialysis requirement in the first week after transplantation. All 164 recipients were followed until 1 year after transplantation. Results: Machine perfusion reduced the incidence of DGF from 69.5% to 53.7% (adjusted odds ratio: 0.43; 95% confidence interval 0.20-0.89; P = 0.025). DGF was 4 days shorter in recipients of machine-perfused kidneys (P = 0.082). Machine-perfused kidneys had a higher creatinine clearance up to 1 month after transplantation (P = 0.027). One-year graft and patient survival was similar in both groups (93.9% vs 95.1%).
K idney grafts can be preserved by either static cold storage or hypothermic machine perfusion. Static cold storage preserves grafts on melting ice after a cold vascular flush with a preservation solution. Hypothermic machine perfusion preserves the graft by continuous or pulsatile administration of a recirculating cold preservation solution (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) • C). Optimal preservation of kidney grafts is essential to reduce the risk of delayed graft function (DGF) after transplantation. 1 Indeed, DGF negatively influences long-term graft survival, is associated with a higher risk of acute rejection, and causes increased mortality in older recipients. [1] [2] [3] [4] DGF inevitably augments postoperative costs because of prolonged hospital stay, the need for dialysis, and additional diagnostic procedures. 5, 6 Currently, because of the persistent donor shortage, kidneys donated after cardiac death (DCD) have become an important additional source of renal allografts in many countries. 7 They have the potential to increase the number of kidney transplantations up to 4.5 times. 7, 8 DCD kidneys suffer from a substantially higher incidence of DGF (28%-88% vs 13%-35%), which seriously limits their use, than kidneys donated after brain death (DBD). 7, 9, 10 This increased rate of DGF is caused by inevitable exposure of these kidneys to renal warm ischemic injury during the period of circulatory arrest. Therefore, optimal preservation of DCD kidneys is crucial to reduce their intrinsically increased risk of DGF and allow a safer and wider use of this potentially large donor source.
Previous studies have suggested that machine perfusion of DCD kidneys results in better early function and improved graft survival than those preserved by static cold storage. [11] [12] [13] Other studies do not support this conclusion, however, and a comprehensive metaanalysis failed to show a statistically significant risk reduction of DGF in machine-perfused versus static cold-stored DCD kidneys.
MATERIALS AND METHODS

Trial Enrolment Criteria
This prospectively planned analysis assessed all consecutive DCD kidney donors reported in Belgium and the Netherlands during the Machine Preservation Trial. The study was fully integrated in the Eurotransplant system that manages waiting lists and organizes organ allocation in a part of western Europe. 18 The trial included only Maastricht category III (cardiac arrest after withdrawal of treatment) DCD donors 16 years or older and a 5 minute "no-touch" period was always respected. 7 A strictly paired design was maintained, in which both kidneys of 1 donor needed to be transplanted into different recipients. Both kidneys of a pair were excluded from the analysis when 1 or both recipients died within 1 week after transplantation. To allow complete integration within Eurotransplant, to reflect current practice, and to ensure the participation of all transplant centers, current standard center protocols were not changed. Informed consent from recipients was not required, as kidneys were randomized before organ allocation. Ethical approval was obtained from the Eurotransplant Ethical Advisory Committee, the Kidney Advisory Committee, and ethics review boards in each trial region.
Randomization
Whenever a potential kidney donor meeting the inclusion criteria was reported, the Eurotransplant duty desk officer randomly assigned 1 kidney to machine perfusion and the contralateral kidney to static cold storage. Randomization lists were computer generated by the permuted block method. We used regional lists to avoid imbalances caused by small differences in allocation algorithms. When a reliable connection to the perfusion machine was impaired by a too small aortic patch or too many renal arteries, randomization for this kidney pair was changed and preservation methods were switched. Kidneys were allocated according to standard Eurotransplant allocation rules, without revealing the preservation method at organ offer. The recipient's surgical team was unblinded at the time of transplantation.
Preservation Methods
Hypothermic machine perfusion was performed with LifePort Kidney Transporter machines (Organ Recovery Systems, Itasca, IL). For the purpose of the study, a trained perfusionist attended each donor procedure to guarantee availability and correct use of the machines. Immediately after organ recovery, the donor surgeon, assisted by the perfusionist, connected the kidney randomized to machine perfusion to the perfusion machine. A pulsatile flow with Kidney Preservation Solution-1 (KPS-1) (1-8
• C) was maintained until transplantation.
19 Systolic perfusion pressure was fixed at 30 mm Hg. Next, the machine-perfused kidney was transported to the recipient hospital without any monitoring. Flow readings and intravascular resistance were concealed to the transplantation team. As a result, the decision to accept or reject a kidney could not be biased by these parameters.
Kidneys randomized to static cold storage were flushed and preserved according to the established Eurotransplant routine, using either University of Wisconsin solution (UW) or histidinetryptophan-ketoglutarate (HTK) according to the center-specific practice. Organs were submerged in the preservation solution and stored on melting ice until transplantation.
Follow-up
No changes to center-specific patient follow-up protocols were made. Eurotransplant established a secure online database in which follow-up data could be provided by participating transplantation centers. To ensure maximal data completeness, recipient centers were financially compensated for providing follow-up data. No relevant irregularities were found during an external audit of a random sample of 10% of all patient follow-up data.
Study Endpoints
The primary endpoint was DGF, defined as the need for dialysis in the first week after transplantation. As a secondary endpoint, early graft function was assessed in a more refined, objective way as functional DGF, which was defined as the absence of a decrease in serum creatinine level by a minimum of 10% per day during 3 consecutive days in the first postoperative week, not including patients in whom acute rejection, calcineurin inhibitor toxicity, or both, developed within the first week. 20 Other secondary endpoints were as follows: duration of DGF, primary nonfunction (PNF), biopsy-proven acute rejection, calcineurin inhibitor toxicity, serum creatinine values, creatinine clearance, length of recipients' hospital stay, and patient and graft survival up to 1 year after transplantation. Data on graft survival were censored at the time of death in patients who died with a functioning graft.
Statistical Methods
All data analyses were performed using SPSS, SAS, and R software. Two-sided P values 0.05 or less indicated statistical significance. The study was powered to detect a reduction in DGF due to machine perfusion of at least 20%, based on a presumed rate of DGF of 70% in the cold storage group. A minimum of 80 kidney pairs were required to obtain a statistical power of 0.8, assuming a univariate 1-sided type I error of 0.05; this is equivalent to the required sample size for a multivariate logistic regression with a 2-sided type I error and similar power. 21 The influence of machine perfusion compared with static cold storage on the risk of DGF was examined by a logistic regression model. 21 Covariate selection was based on relevant literature and prespecified in the protocol before the trial started. 22, 23 To better reflect the paired study design, all covariates were entered in the analysis with a built-in normal-gamma frailty term for the donor. Demographic variables were analyzed by the Fisher exact test or the Mann-Whitney test. We applied the McNemar test or the Wilcoxon signed-rank test to evaluate univariate differences in endpoint variables between the 2 groups. Assessment of graft and patient survival was done by the Kaplan-Meier method and differences between survival curves were determined by log-rank tests. Endpoint interim analyses were not performed, but confidential safety analyses comparing reported rates of adverse events in the 2 study groups were conducted at regular intervals by the trial safety board.
Role of Funding Source
An independent scientific steering committee comprising clinicians and scientists from each trial region was responsible for the design, conduct, data analysis, and manuscript preparation for this study. The sponsor was not involved in the study design, follow-up data acquisition, data analyses, or writing of the manuscript. During the course of this trial, the sponsor provided the trial regions with machine perfusion devices and disposables free of charge and operated a 24-hour helpline that could be consulted by perfusionists in case of perfusion device-related technical issues. trial, the steering committee anticipated that insufficient DCD kidney pairs would be included to perform relevant analyses for the prespecified DCD subgroup. Inclusion of DCD donors therefore was continued in a second phase (November 1, 2006, to August 17, 2007) adhering to the protocol of the Machine Preservation Trial. The flow diagram (Fig. 1) shows enrolment and randomization of kidney pairs for the present study. Two hundred four potential DCD FIGURE 1. Consort diagram showing enrolment and randomization of donors kidney pairs in the trial.
a Technical machine-related problems caused the machine to switch to the "fail safe" mode and led to cold storage of the kidney inside the machine. These kidneys remained suitable for transplantation but were excluded from analysis in the present study. Because the machine perfusion pump is pressure controlled, the "fail safe" mode is activated when a risk of possible barotrauma is detected. This occurred in 3 cases: (1) a sudden change in surrounding pressure during transport misguided the software, (2) a high resistance alarm, and (3) leakage of the perfusion fluid. kidney donors were assessed for inclusion, 103 kidney pairs were included, and data from 82 recipients in each study group were analyzed. In 9 cases, the connection of the kidney randomized to machine perfusion was unreliable because of aberrant vascular anatomy and therefore preservation methods of both kidneys were switched. Vascular anomalies, however, did not significantly increase the risk of DGF (data not shown, P = 0.064). Table 1 shows the characteristics of kidney donors and recipients. Eighty-two recipients were included in each study group. There were no significant differences between the groups with respect to donor and recipient age, duration of pretransplant dialysis, number of previous transplants, panel reactive antibodies, cold ischemic time, flush solution, induction therapy, and maintenance immunosuppression regimens.
Study Group Characteristics
Primary Endpoint
Forty-four recipients in the machine perfusion group and 57 recipients in the static cold storage group developed DGF (53.7% vs 69.5%; P = 0.007) ( Table 2 ). Multivariate analysis (Table 3) showed a decreased probability of developing DGF in machine-perfused versus static cold-stored DCD kidneys (adjusted odds ratio: 0.43; 95% confidence interval: 0.20-0.89; P = 0.025). Other significant risk factors for DGF were donor and recipient age and warm and cold ischemic times. Table 2 shows the univariate analysis of all secondary endpoints. Functional DGF occurred in 16 recipients in the machine perfusion group versus 42 recipients in the static cold storage group (19.5% vs 51.2%; P < 0.0001). The median duration of DGF in the machine perfusion group was 4 days shorter than in the static cold storage group, but this difference did not reach statistical significance (9 days vs 13 days; P = 0.082). However, DGF was more likely to be shorter than 7 days in a machine-perfused kidney than in a static cold-stored kidney. There were no differences in the median length of recipients' hospital stay. PNF occurred in only 2 cases in each study group. Creatinine clearance was significantly higher in the machine perfusion group until 1 month after transplantation. At 1 year follow-up, 3 patients in the machine perfusion group and 2 patients in the static cold storage group had died. Graft survival at 1 year follow-up was similar in both groups (93.9% vs 95.1%) (Fig. 2) . 20 Recipients developing acute rejection or calcineurin inhibitor toxicity within the first week were excluded from this category.
Secondary Endpoints
‡Primary nonfunction: permanent lack of graft function. causes morbidity and even mortality in older recipients, and leads to additional costs. [1] [2] [3] [4] [5] [6] DCD kidneys are currently accepted by many transplant centers as an additional donor source and the potential of DCD kidneys is large. Because DCD kidneys are intrinsically more prone to developing DGF, decreasing the incidence of DGF by machine perfusion will be particularly beneficial for recipients of this type of kidney graft. 7, 9, 10 In the multivariate analysis, machine perfusion clearly reduced the risk of DGF. Furthermore, DGF was more likely to be short lasting (<7 days) in machine-perfused kidneys than in static cold-stored kidneys. We also explored the impact of machine perfusion on functional DGF, which is a more refined surrogate marker for early kidney graft function than DGF defined as dialysis requirement in the first postoperative week. 20 We found that the incidence of functional DGF was strongly reduced by machine perfusion, even more than the incidence of DGF. Hence, the protective effect of machine perfusion shown in our study may be underestimated when using only the traditional definition of DGF as an outcome measure. However, we selected the traditional definition of DGF as the primary endpoint to allow for comparison of the results in the present analysis with those from previous studies. Our observation that creatinine clearance in recipients of machine-perfused kidneys was higher early after transplantation shows that actual early kidney function is also superior after machine perfusion.
FIGURE 2.
Death censored allograft survival at 1 year after transplantation. Graft survival in the machine perfusion versus the static cold storage group was similar (94% vs 95%) (log-rank test of equality: P = 0.7).
Our study confirmed that donor age and cold ischemic time are independent risk factors for DGF in DCD kidneys, even though cold ischemic times were relatively short in both groups. 22, 23 Cold ischemic time was slightly but not significantly longer in the static cold-stored group. However, with a previously reported odds ratio of 1.23 of DGF for every 6-hour increase in cold ischemic time, 24 it is unlikely that these additional 54 minutes of cold ischemia caused a major bias of the primary endpoint. Moreover, the study revealed that the duration of warm ischemia is a more important independent additional risk factor for DGF.
Even though DGF is a risk factor for graft failure after kidney transplantation and machine perfusion significantly reduced the risk for DGF, our study did not show improvement in 1-year graft survival of machine-perfused versus static cold-stored kidneys. [1] [2] [3] We cannot exclude that the young donor age in our cohort in part masked an advantage of machine perfusion on graft survival. Nevertheless, this finding is in line with an increasing number of reports showing similar medium-term graft survival for DCD and DBD kidneys despite higher rates of DGF in DCD kidneys.
7,10,25 DGF does not influence graft survival after DCD kidney transplantation in the same way it does after DBD kidney transplantation. This could be explained by a possibly different nature of DGF in DCD versus DBD kidneys. The metabolic, hemodynamic, hormonal, and inflammatory changes that occur after brain death and during donor management, but not after cardiac death, may impair kidney function more and could have more long-term impact than warm ischemic injury alone. 26, 27 The present study yielded a few surprising results. First, despite the significant reduction of DGF by machine perfusion, the incidence of PNF was not reduced. A PNF incidence of only 2.4% may seem surprisingly low. The exclusion of uncontrolled (Maastricht category I and II) DCD donors who are more prone to PNF and the relatively short median warm and cold ischemic times in our donor population may account for the low rate of PNF. However, when compared with reported PNF incidences in other series of controlled DCD kidney transplantations (0%-17%) and the previously conducted main trial (1/42), the observed incidence of PNF was not exceptionally low. 11, 12, 14, 17, 28, 29 Nevertheless, it is likely that the overall incidence of PNF was too low to detect an effect of machine perfusion. Second, hospital stay is usually longer in recipients of DCD versus DBD kidneys because of the increased rate of DGF in the former group. 10 Despite reduced duration and severity of DGF, our study showed no significant reduction in hospital stay for recipients of machineperfused kidneys. This unexpected observation may, at least in part, be explained by the fact that the trial was conducted in Eurotransplant countries. Healthcare systems with greater pressure to limit the use of resources will have a tendency toward shorter hospital stay. 30, 31 We believe that in countries with such a healthcare system, the reduction in DGF seen in our trial might be paralleled by a significant reduction in hospital stay. This observation also reflects the relative unreliability of hospital stay as a valid outcome parameter, as suggested by other studies.
To date, no definitive evidence of the superiority of machine perfusion over cold storage for the preservation of DCD kidneys has been available. Although an advantage of machine perfusion has been suggested, all previous studies were relatively small in size compared with the present prospective trial. [11] [12] [13] 16 The effect of machine perfusion on DCD kidney preservation was recently studied in the United Kingdom. A randomized controlled trial with sequential analysis suggested that machine perfusion of DCD kidneys does not decrease DGF. 29 Differences in study design may account for this discrepancy. The present trial was not only larger but also fully integrated into Eurotransplant. Kidneys were allocated strictly and solely according to standard Eurotransplant rules, and recipient centers were blinded to the preservation method at the time of organ offer. Furthermore, all kidneys were perfused immediately after retrieval until transplantation, which was not necessarily the case in other studies. The need to perfuse kidneys immediately after retrieval to benefit fully from the "perfusion effect" needs to be investigated further, as this practice has important logistic consequences.
The present study has some limitations. The strictly paired design of the trial, and the necessity to randomize kidney pairs immediately after the report of a potential donor, accounts for the large number of exclusions. First, donor kidney pairs, of which 1 kidney was not transplanted, were excluded, possibly leaving kidneys with Copyright © 2010 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. a higher risk of DGF out of the study. Second, less hemodynamically stable donors, in whom organ recovery had to be performed as an emergency procedure, could not always be reached in time. Another possible limitation is the difference in preservation solutions in both groups. Only 1 pharmaceutical formulation of machine preservation solution is Food and Drug Administration approved; therefore, machine-perfused kidneys were preserved with KPS-1. Static coldstored kidneys were preserved in HTK (75.6%) or UW (22.0%), and although UW is still the gold standard for cold storage of kidneys, analysis of the United Network of Organ Sharing data showed that HTK preservation has no effect on DGF compared with UW. 32 In conclusion, this international randomized, controlled trial showed that hypothermic machine perfusion of DCD kidneys reduced the risk of DGF and improved graft function until 1 month after transplantation. When DGF occurred, it was of a shorter duration and less severe. We therefore suggest that machine perfusion should be routinely used for the preservation of DCD kidneys. Apart from being beneficial to the individual patient, these protective effects of machine perfusion might result in a substantial reduction of DGF-related costs. The cost-effectiveness of hypothermic machine perfusion however remains to be investigated. 
DISCUSSION
DISCUSSANTS R. Margreiter (Innsbruck, Austria)
In the article, you said that informed consent was not required and kidneys were randomized before allocation. Do patients agree to accept a kidney from an non-heart-beating kidney donor when they are put on the waiting list in the Netherlands and in Belgium?
For machine perfusion, you were using "Preservation Solution 1." Could you tell us what kind of solution this is? Patients who developed acute rejection or calcineurin inhibitor toxicity within the first week were excluded from functional delayed graft function assessment. To do so, you would have needed to obtain biopsy specimens from every patient who experienced initial nonfunction. Did you do that?
Initially, you had 103 pairs of kidneys but only 82 pairs were analyzed; 9 kidneys were excluded because the connection with the machine was not reliable. What were the reasons to exclude the remaining 12 pairs? Twenty-one kidneys had a warm ischemia time of less than 10 minutes, which is extremely short. How was cardiac death diagnosed?
Most groups wait 5 to 10 minutes after cardiac arrest to make sure that donors are also brain dead. Obviously, you do not do that. Could you comment on that?
In the static cold storage group, 57 patients suffered from delayed graft function that required dialysis. How can a further 42 patients of this group of 82 patients be diagnosed with functional delayed graft function because 57 + 42 gives 99.
Response From I. Jochmans
Indeed, in the article, we do state that consent from recipients was not obtained. This is due to the specific construction of the trial in which the randomization of the kidneys had to be done before allocation of the kidneys. Patients on the waiting list are informed that they can be allocated a kidney from a DCD donor. So yes, they are informed before transplantation.
Regarding the solution we used to perfuse the kidneys, this is called Kidney Preservation Solution-1 or KPS-1. It is the standard type of machine perfusion solution with the same composition as originally formulated by F. O. Belzer and James Southard at the University of Wisconsin. It is a gluconate-based perfusate that contains hydroxyl-ethyl starch, such as UW. In comparison with UW, however, KPS-1 contains a low potassium content to avoid vasoconstriction. Thus, KPS-1 is a standard accepted machine perfusion solution used worldwide.
Next, if I recall correctly, your question was whether we performed a biopsy on all patients with initial nonfunction. Yes, biopsy specimens were obtained.
When the connection of a particular kidney to the machine was not reliable, the randomization scheme was switched, but the kidney pair was not excluded from the trial. One hundred three kidney pairs were allocated and indeed 82 pairs were finally analyzed. If I recall correctly, 10 of the static cold storage kidneys and 1 machine-perfused kidney were deemed not transplantable by the donor surgeons at the time of procurement; in 2 cases, we did not find a suitable recipient for the kidneys, in 3 cases the machine failed and the kidneys were not perfused but only cold stored within the machine, and, finally, 3 recipients died within 1 week after transplantation. These kidney pairs were excluded.
Concerning your question on warm ischemia and the "notouch" period, the diagnosis of cardiac death was made by 3 physicians not in any way related to the procurement team. The length of warm ischemia period was calculated from the start of cardiac arrest until cold flushing of the kidneys. We did and always do respect a no-touch" There is a too many period of 5 minutes in all cases. Warm ischemic times could be kept short in centers where the switch off occurred in the operating theatre, which is mostly the case in Belgium. In the Netherlands, the switch-off procedure and diagnosis of cardiac death was most often done in the intensive care unit.
Finally, to address your question about DGF and functional DGF, the definitions of DGF and functional DGF are not mutually exclusive. Patients with DGF needing dialysis also fit the definition of functional DGF (absence of a decrease in serum creatinine level of at least 10% per day for 3 consecutive days in the first week after transplantation).
DISCUSSANTS W. Bechstein (Frankfurt, Germany)
It has been claimed that machine perfusion allows identification of kidneys that will never work, especially in extended criteria donors. However, in your article the rate of PNF or kidneys that never functioned was the same in both arms. Can you comment? Second, you said that the recipient centers were blinded as to whether they received machine-perfused kidneys or normal cold storage kidneys.
However, if I understand correctly, the kidneys were shipped either in a cold storage bag or with machine perfusion. So in the end, the centers were not blinded. Could this have influenced their management decisions with regard to dialysis, which would have an influence on your primary endpoint?
Response From I. Jochmans Indeed, the incidence of PNF in our trial was low and comparable between the study arms. We used machine perfusion as a preservation method, not to assess graft quality. Kidneys were accepted based on standard donor criteria. We only included controlled Maastricht category III DCD donors with a relative short median warm ischemic time, which probably accounts for the low incidence of PNF. We only experienced 2 cases of PNF in the machine perfusion group and also 2 in the static cold storage group. This incidence might seem extraordinarily low but does compare with incidences of PNF reported in other studies with type III DCD donors, in which incidences are described between 0% to more than 10%. Obviously, we saw too few events to find any benefit of machine perfusion on the PNF endpoint. To determine the benefit of machine preservation on PNF, we should look at Maastricht category I and II uncontrolled donors (death on arrival or unsuccessful resuscitation). However, both in Belgium and in the Netherlands, these types of donors are less commonly used. Spain and France have more experience with uncontrolled donors, but to my knowledge, there is no randomized controlled study comparing static cold storage and machine preservation in these donor types.
With regard to your question as to the blinding of the study, indeed, at the moment of organ offer and the decision to accept this particular kidney, the centers were not aware of the preservation method. The decision to accept or reject a particular kidney was based solely on standard donor criteria. Obviously, when the kidney arrived in the operating room, the operating team was unblinded. There is indeed a small possible bias that could have influenced the decision to start dialysis. However, in most of the participating centers, patients are followed by nephrologists and the decision to dialyze is not primarily made by the operative team. We also determined the effect of machine perfusion on functional DGF, which is a more refined and objective definition of kidney dysfunction after transplantation, where the effect of bias would be even lower.
DISCUSSANTS T. Van Gulik (Amsterdam, the Netherlands)
For the first time, this study provides the evidence for something we have always believed in organ preservation, namely, that machine perfusion is superior to conventional cold storage for preservation of DCD kidneys.
I would like to expand a little further on Dr Margreiter's questions. You used the modified UW solution for machine perfusion. The disadvantage of this solution is that it is viscous. For the initial washout, one would prefer a less viscous solution and that is why, usually, in this category of donors, the HTK solution is used for the washout. My question is: How did you perform the washout? Did you use your perfusion solution, the modified UW solution? Or did you use HTK solution, which is more or less the standard in these patients?
My second question relates to another very important advantage of machine perfusion, which is that it allows you to monitor the quality of the graft during the preservation period. You showed in your slides that you looked at biomarkers and specifically at parameters such as perfusion pressure, which relates to intraorgan resistance. Could you predict the outcome of the graft by looking at these parameters in the preservation period?
Copyright © 2010 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Response From I. Jochmans
The initial washout of the kidneys was done according to the practice of the donor center, so either HTK or UW was used. I do not know by heart how many centers used HTK or how many centers used UW, but because it was a paired study, there was obviously no difference in the initial flush between both study arms. We allowed the centers to keep their standard procedures.
As to viability testing using biomarkers and renal resistance, I do not know if we have the time to elaborate further on that, but I would be happy to do it after the session.
In short, we looked into this in 2 amendments to the main trial in which we determined biomarkers in the perfusate and also looked at renal resistances. The take-home message is that both of them are correlated with, and are independent predictors of, delayed graft function but not PNF. Again, we have very few PNFs in our study. Neither the biomarkers nor the renal resistance should be used by itself to discard kidneys but can be used as an additional tool in assessing the risk of delayed graft function of a particular kidney.
DISCUSSANTS P. A. Clavien (Zurich, Switzerland)
Our group previously showed that delayed graft function leads to different outcomes and is therefore possibly related to different mechanisms of injury in grafts obtained from donors after cardiac death versus those obtained after brain death. We observed that delayed graft function in an organ obtained from a donor after cardiac death had no impact on the long-term outcome of kidney function and patient survival, whereas a similar degree of initial poor function was associated with much poorer outcome in grafts arising from a brain dead donor. This leads to my question: From your exhaustive data in this trial, could you tell us more about potential mechanisms of injury or protection between grafts from donors after cardiac versus brain death? This could also help us to better understand why machine perfusion also works in grafts after cardiac death.
Response From I. Jochmans
Why delayed graft function in a brain dead donor kidney is of a different nature than delayed graft function in a cardiac dead kidney is something I cannot answer for certain. In the literature, it has been suggested that the inflammatory cytokine storm and hormonal changes that occur in brain dead patients and during the management of these types of donors might play a role. This is obviously not present in cardiac dead donors, but to my knowledge, there is no strong definite evidence for this yet. We are currently looking at donor complement in plasma and tissue biopsies to try and find an explanation for the differences in the nature of DGF between DBD and DCD kidneys. Also, why machine perfusion works remains an open question.
DISCUSSANTS C. Broelsch (Essen, Germany)
I do hear some of Fred Belzer's old stories repeated; it was originally designed to extend cold ischemia time to allow for longdistance transportation of these organs. However, I would like to raise a point as a German surgeon: the criteria for death in DCD donors are not accepted in Germany. This is different from other countries. The issue being addressed in your study does not allow German surgeons to even touch or use these organs. So, we talk about a European study, which is, as you showed very nicely, confined to the Benelux countries. I am not aware whether Austria or other countries such as Slovenia allow for DCD criteria, but it might come up as a problem. Thus, caution is advised; I deliberately raised this issue with German surgeons and others who are not allowed to use DCD donor organs.
Response From I. Jochmans
You are absolutely right; the legal and ethical framework for DCD donors differs between countries worldwide. Caution is indeed still warranted. A thorough preparation of DCD protocols is necessary to avoid misunderstanding and misinterpretation by the medical society and the general public.
In Eurotransplant, only Belgium and the Netherlands have the proper legal framework. In contrary to the main trial in which Germany was also one of the participating countries, Germany did not provide any donors or accept any of these DCD kidneys.
